key: cord-0877779-sz3u09j9 authors: Shabani, Mehdi; Ehdaei, Bahar Sadegh; Fathi, Farshid; Dowran, Razieh title: A mini-review on Sofosbuvir and Daclatasvir treatment in COVID-19 date: 2021-05-07 journal: New Microbes New Infect DOI: 10.1016/j.nmni.2021.100895 sha: 6925c9f91ac6e291654ca88139a0a1c953a0cdd3 doc_id: 877779 cord_uid: sz3u09j9 Sofosbovir and daclatasvir have been used successfully since 2013 for hepatitis C virus treatment .It has been shown by different studies that sofosbovir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between HCV RNA polymerase and SARS-CoV-2 has also been established. The efficacy of sofosbuvir and daclatsvir as potential choices in treating patients with COVID-19 and their recovery can be hypothesized. with HCV being the major risk factor (4). HCV is classified into seven genotypes(5). Noteworthy is the fact that genotypes 1, The NS proteins include two viral proteases, i.e., a zinc-stimulated NS2-3 protease 40 and the NS3 serine protease, which are responsible for cleavages the NS region of 41 the HCV poly protein, an RNA helicase located in the carboxy-terminal region of 42 NS3, the NS4A polypeptide, the NS4B and NS5A proteins, and a RNA-dependent 43 RNA polymerase (RdRp) represented by NS5B(12). The standard treatment for HCV infection was peg-interferon (PEG-IFN) with 45 ribavirin (RBV) for 48 weeks. However, this was effective in only 30% of patients. J o u r n a l P r e -p r o o f The combination of a first-generation protease inhibitor (telaprevir or boceprevir) 47 with PEG-IFN and RBV subsequently improved sustained virological response 48 (SVR) rates to 50%-65% in genotype 1 HCV-infected recipients(13). However, the 49 addition of boceprevir or telaprevir is limited to HCV genotype 1 and is associated 50 with side-effects, intricate dose regimens, and viral resistance (14). The 12-week administration, i.e., once-daily oral daclatasvir plus sofosbuvir, with Calu-3 cells is also inhibited by sofosbuvir; its efficiency in the liver, however, is 167 higher than the lung. In future clinical trials, the two issues of effectiveness and 168 safety should be considered in the treatment of COVID-19 with sofosbuvir and 169 daclatasvir. The molecular biology of coronaviruses Prevalence of hepatitis C infection among the general 175 population and high-risk groups in the EU/EEA: a systematic review update Liver transplantation in the 178 United States Epidemiology of viral hepatitis and hepatocellular carcinoma Expanded classification of 182 hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web 183 resource The global health burden of hepatitis C virus infection A systematic review of 187 hepatitis C virus epidemiology in Europe, Canada and Israel The epidemiology of hepatitis C virus in Iran: 189 systematic review and meta-analyses Clinical and serological 191 analysis of transfusion-associated hepatitis. The Lancet Isolation of a cDNA clone 193 derived from a blood-borne non-A, non-B viral hepatitis genome Hepatitis C virus shares amino acid sequence similarity with pestiviruses 195 and flaviviruses as well as members of two plant virus supergroups Hyperphosphorylation of the hepatitis C virus NS5A 198 protein requires an active NS3 protease, NS4A, NS4B, and NS5A encoded on the same polyprotein Safety and efficacy of 201 protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience Boceprevir for 204 untreated chronic HCV genotype 1 infection Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection Chemical genetics 209 strategy identifies an HCV NS5A inhibitor with a potent clinical effect Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Current 211 opinion in virology All-oral 12-week treatment 213 with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III 214 study Daclatasvir 216 plus sofosbuvir for HCV in patients coinfected with HIV-1 Genome composition and divergence of the 219 novel coronavirus (2019-nCoV) originating in China. Cell host & microbe Structural insights into coronavirus entry A pneumonia outbreak associated 223 with a new coronavirus of probable bat origin Receptor recognition by the novel coronavirus from 225 Wuhan: an analysis based on decade-long structural studies of SARS coronavirus 228 The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against 229 SARS-CoV-2. bioRxiv Sofosbuvir as repurposed antiviral drug against COVID-19: 231 why were we convinced to evaluate the drug in a registered/approved clinical trial? Archives of medical 232 research Discovering drugs to treat coronavirus disease 2019 (COVID-19) Direct acting anti-hepatitis C virus drugs: 236 clinical pharmacology and future direction A SARS-CoV-2-Human Protein-240 Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing silico studies on therapeutic agents for COVID-19: Drug repurposing 242 approach. Life Sciences Sofosbuvir: a review of its use in patients with chronic hepatitis C GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C 246 virus infection. Expert review of anti-infective therapy Mechanism of activation of PSI-248 7851 and its diastereoisomer PSI-7977 No Resistance 250 Detected in four Phase 3 Clinical Studies in HCV Genotype 1-6 of Sofosbuvir+ Ribavirin with or without 251 Peginterferon: 1843 Sofosbuvir for 253 previously untreated chronic hepatitis C infection Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options All-oral 259 therapy with sofosbuvir plus ribavirin for the treatment of Hcv Genotype 1, 2, and 3 infection in patients 260 co-infected with Hiv (photon-1): 212 New concepts of sofosbuvir-based treatment regimens 262 in patients with hepatitis Overall efficacy and safety results of sofosbuvir-based therapies in phase 264 II and III studies Nucleotide Analogues as Inhibitors 266 of SARS-CoV-2 Polymerase Nucleotide analogues as inhibitors of SARS-268 CoV polymerase Beyond 270 members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication. Antimicrobial 271 agents and chemotherapy The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs 274 daclatasvir and sofosbuvir against SARS-CoV-2 Evaluation of 278 sofosbuvir activity and resistance profile against West Nile virus in vitro